IL32 and gastric cancer: Based on the report, IL-32 is highly expressed in patients with pancreatic cancer or gastric cancer and IL-32 has pro-cancer effects that inhibit apoptosis, stimulate DNA synthesis in the proliferation of cancer cells, and increase invasion associated with tumor progression and metastasis [33,34,35,36].